[Ovarian carcinoma. Do the subtypes reflect different diseases?].
Lack of therapeutic options and poor reproducibility of histopathological subtypes have been the reasons that ovarian carcinomas are currently treated as monolithic entity. Histopathological grading is used to identify those patients who can be spared adjuvant therapy. With slight modifications of the WHO based subtype classification we have shown that subtypes (i.e. serous, endometrioid, clear cell, mucinous) can be reproducibly used to stratify patients according to disease-specific survival. As these pathologically identifiable subtypes have different epidemiologic and genetic risk factors, precursor lesions, molecular abnormalities and clinical behaviour, screening and management strategies have to be subtype-specific.
Köbel
M
M
Department of Pathology Genetic Pathology Evaluation Centre, Vancouver General Hospital and the University of British Columbia, West 10th Avenue, V5Z 4E3 Vancouver, BC, Canada. martin.koebel@vch.ca
D018262:Adenocarcinoma, Clear Cell / Q000145:classification / Q000235:genetics / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000145:classification / Q000235:genetics / Q000473:pathology; D018269:Carcinoma, Endometrioid / Q000145:classification / Q000235:genetics / Q000473:pathology; D018284:Cystadenocarcinoma, Serous / Q000145:classification / Q000235:genetics / Q000473:pathology; D004252:DNA Mutational Analysis; D003937:Diagnosis, Differential; D005260:Female; D005819:Genetic Markers / Q000235:genetics; D006801:Humans; D015588:Observer Variation; D010051:Ovarian Neoplasms / Q000145:classification* / Q000235:genetics / Q000473:pathology*; D010053:Ovary / Q000473:pathology; D017410:Practice Guidelines as Topic; D011379:Prognosis; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
D005819:Genetic Markers; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53